Alector Inc
(STU:0Z2)
€
1.69
-0.07 (-3.98%)
Market Cap: 167.26 Mil
Enterprise Value: -238.19 Mil
PE Ratio: 0
PB Ratio: 1.47
GF Score: 55/100 Alector Inc at Bank of America NAPA Healthcare Conference Transcript
Jun 14, 2021 / 09:30PM GMT
Release Date Price:
€15.9
(+1.92%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Welcome to the afternoon sessions of the Second Annual Virtual Napa conference. Next here will be the real thing. Fingers crossed. My name is Geoff Meacham, I'm the senior biopharma analyst here, and I have Alex Hammond from my team with me as well. And we're thrilled to have Alector with us for this last session and speaking on behalf of Alector is President and COO, Shehnaaz Suliman. How are you doing, Shehnaaz? It's good to see you.
Shehnaaz Suliman
Alector, Inc. - President, COO & Interim Chief Business Officer
Doing great. Thanks for having us.
Questions & Answers
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Yes. So we'll start it off with maybe just sort of a recap of the events of early last week with Biogen's aducanumab obviously, doesn't directly affect you, but I wanted to kind of get your thoughts of the FDA decision and maybe what that means for Alzheimer's or
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot